Designation of Ruxolitinib Jakavi as an orphan drug - Novartis Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the provision of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. The 2014 designation of Ruxolitinib JAKAVI as an orphan drug is a specific action under this Act, aimed at addressing the medical needs of patients with rare conditions. This designation, introduced by the Department of Health's Therapeutic Goods Administration, seeks to promote the development and availability of treatments for diseases that affect a small number of people in Australia. The policy objective is to incentivise the development of medicines for rare diseases by providing certain benefits to the sponsor, in this case, Novartis Pharmaceuticals Australia Pty Ltd, facilitating access to such critical therapies for underserved patient populations.

Scope and Application

The Therapeutic Goods Act 1989, as applied in the designation of Ruxolitinib JAKAVI as an orphan drug, applies to entities and persons involved in the development, approval, and marketing of therapeutic goods within Australia. Specifically, this designation pertains to Ruxolitinib JAKAVI, which is indicated for the treatment of patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. The Act's jurisdictional reach is at the Commonwealth level, administered by the Therapeutic Goods Administration (TGA), thereby impacting the pharmaceutical industry and the medical community across the nation. The Act does not explicitly outline exclusions or exemptions in this specific designation; however, its broader application may be influenced by other sections of the Act and its regulations, which can extend or restrict application through subordinate instruments. The designation as an orphan drug is intended to encourage the development of treatments for rare diseases by providing certain incentives to the sponsor, in this case, Novartis Pharmaceuticals Australia Pty Ltd.

Key Provisions

The Therapeutic Goods (Designation of Ruxolitinib JAKAVI as an Orphan Drug) Determination 2014 designates Ruxolitinib JAKAVI as an orphan drug (s 16J of the Therapeutic Goods Regulations 1990) for the treatment of patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. This designation recognises the rarity of the condition and the need for specific treatments that address the unique challenges faced by these patients. Ruxolitinib JAKAVI is to be administered in tablet form for this specific indication. Entities governed by the Act, including the sponsor Novartis Pharmaceuticals Australia Pty Ltd, are required to ensure that Ruxolitinib JAKAVI meets the criteria for orphan drug designation as outlined in the Regulations. This includes providing evidence that the drug is intended for a rare condition and that there is a significant benefit for patients who have limited or no alternative treatment options. The sponsor must also comply with other regulatory requirements, such as those related to the quality, safety, and efficacy of the therapeutic good. Failure to comply with the obligations set out in the Act and Regulations may result in regulatory action. Under the Therapeutic Goods Act 1989, breaches can lead to a range of civil and criminal penalties. For example, offences involving misleading or deceptive conduct can result in fines of up to $1.1 million for a corporation and imprisonment for up to five years for an individual. Additionally, the Therapeutic Goods (Regulatory Action) Regulations 2012 provide for further penalties, including the possibility of product recalls and court-ordered corrective advertising. The Therapeutic Goods Administration is responsible for enforcing compliance and taking appropriate action against entities that fail to adhere to the requirements of the Act and Regulations.